A Clinical Trial about a Food Supplement Containing α-Lipoic Acid on Oxidative Stress Markers in Type 2 Diabetic Patients
- PMID: 27801825
- PMCID: PMC5133803
- DOI: 10.3390/ijms17111802
A Clinical Trial about a Food Supplement Containing α-Lipoic Acid on Oxidative Stress Markers in Type 2 Diabetic Patients
Abstract
The aim of this study was to evaluate the effect of a food supplement containing α-lipoic acid and of a placebo on glyco-metabolic control and on oxidative stress markers in type 2 diabetics. We randomized 105 diabetics to either a supplementation containing 600 mg of α-lipoic acid, 165 mg of L-carnosin, 7.5 mg of zinc, and vitamins of group B, or a placebo, for three months. We evaluated body mass index, fasting plasma glucose (FPG), post-prandial-glucose (PPG), glycated hemoglobin (HbA1c), fasting plasma insulin (FPI), HOMA-index (HOMA-IR), lipid profile, high sensitivity C-reactive protein (Hs-CRP), superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), malondialdehyde (MDA). There was a reduction of FPG, PPG, and HbA1c with the food supplement containing α-lipoic acid compared with a baseline, and with the placebo. Concerning lipid profile, we observed a reduction of LDL-C, and Tg with the food supplement, compared with both the baseline, and the placebo. There was a reduction of Hs-CRP with the food supplement containing α-lipoic acid, both compared with the baseline and the placebo. An increase of SOD, and GSH-Px, and a decrease of MDA were reached by the food supplement containing α-lipoic acid, both compared with the baseline and the placebo. We can conclude that the food supplement containing α-lipoic acid, L-carnosin, zinc, and vitamins of group B improved glycemic control, lipid profile, and anti-oxidative stress markers.
Keywords: L-carnosin; malondialdehyde; oxidative stress; α-lipoic acid.
Conflict of interest statement
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript.
Figures
References
-
- Aring A.M., Jones D.E., Falko J.M. Evaluation and prevention of diabetic neuropathy. Am. Fam. Physician. 2005;71:2123–2128. - PubMed
-
- Grasso S., Bramanti V., Tomassoni D., Bronzi D., Malfa G., Traini E., Napoli M., Renis M., Amenta F., Avola R. Effect of lipoic acid and α-glyceryl-phosphoryl-choline on astroglial cell proliferation and differentiation in primary culture. J. Neurosci. Res. 2014;92:86–94. doi: 10.1002/jnr.23289. - DOI - PubMed
-
- Bramanti V., Tomassoni D., Bronzi D., Grasso S., Currò M., Avitabile M., Li Volsi G., Renis M., Ientile R., Amenta F., et al. α-lipoic acid modulates GFAP, vimentin, nestin, cyclin D1 and MAP-kinase expression in astroglial cell cultures. Neurochem. Res. 2010;35:2070–2077. doi: 10.1007/s11064-010-0256-6. - DOI - PubMed
-
- Kramer K., Packer L., Hoppe P. R-α-Lipoic Acid. Nutraceuticals in Health and Disease Prevention. Marcel Dekker, Inc.; New York, NY, USA: 2001. pp. 129–164.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
